Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996800910> ?p ?o ?g. }
- W1996800910 endingPage "389" @default.
- W1996800910 startingPage "381" @default.
- W1996800910 abstract "Study objective We compare the effects of postinjury administration of allopregnanolone, a metabolite of progesterone, to progesterone in an animal model of transient middle cerebral artery occlusion. Methods Focal cerebral ischemia was induced in age-matched, adult, male, Sprague-Dawley rats by using an intraluminal filament and suture method to occlude the right middle cerebral artery. After 120 minutes of middle cerebral artery occlusion, the occluding filament was withdrawn to allow reperfusion. Laser-Doppler flowmetry was used to monitor cerebral blood flow for the entire 2-hour period of occlusion and for 5 minutes after reperfusion. Animals subjected to middle cerebral artery occlusion received injections of allopregnanolone (8 mg/kg, n=6), progesterone (8 mg/kg, n=6) and vehicle (2-hydroxypropyl-β-cyclodextrin, n=7) at 2 hours (intraperitoneally 5 minutes before reperfusion) and 6 hours (subcutaneously) postocclusion. Brains were removed at 72 hours post–middle cerebral artery occlusion, sectioned into coronal slices, and stained with 2,3,5-triphenyltetrazolium chloride (TTC). In a blinded analysis, infarct volume was calculated by using computer-aided morphometry to measure brain areas not stained with TTC. Results After progesterone or allopregnanolone treatment, stained sections revealed a significant reduction in cortical, caudate-putamen, and hemispheric infarct volumes (percentage of contralateral structure) compared with vehicle-injected controls. Cortical infarction (percentage of contralateral cortex) was 37.47%±10.57% (vehicle), 25.49%±7.38% (progesterone; P<.05 from vehicle), and 11.40%±7.09% (allopregnanolone; P<.05 from vehicle; P<.05 from progesterone). Caudate-putamen infarction (percentage of contralateral caudate-putamen) was 78.02%±22.81% (vehicle), 48.41%±22.44% (progesterone; P<.05 from vehicle), and 50.44%±10.90% (allopregnanolone; P<.05 from vehicle). Total hemispheric infarction (percentage of contralateral hemisphere) was 24.37%±6.69% (vehicle), 15.95%±3.59% (progesterone; P<.05 from vehicle), and 11.54%±3.71% (allopregnanolone; P<.05 from vehicle). No significant differences in cerebral blood flow between groups and time points during ischemia and early reperfusion were observed, suggesting that the relative ischemic insult was equivalent among all groups. Conclusion Although progesterone and allopregnanolone are effective in reducing infarct pathology, allopregnanolone is more potent than progesterone in attenuating cortical damage. Our results suggest that both neurosteroids should be examined for safety and efficacy in a clinical trial for ischemic stroke. We compare the effects of postinjury administration of allopregnanolone, a metabolite of progesterone, to progesterone in an animal model of transient middle cerebral artery occlusion. Focal cerebral ischemia was induced in age-matched, adult, male, Sprague-Dawley rats by using an intraluminal filament and suture method to occlude the right middle cerebral artery. After 120 minutes of middle cerebral artery occlusion, the occluding filament was withdrawn to allow reperfusion. Laser-Doppler flowmetry was used to monitor cerebral blood flow for the entire 2-hour period of occlusion and for 5 minutes after reperfusion. Animals subjected to middle cerebral artery occlusion received injections of allopregnanolone (8 mg/kg, n=6), progesterone (8 mg/kg, n=6) and vehicle (2-hydroxypropyl-β-cyclodextrin, n=7) at 2 hours (intraperitoneally 5 minutes before reperfusion) and 6 hours (subcutaneously) postocclusion. Brains were removed at 72 hours post–middle cerebral artery occlusion, sectioned into coronal slices, and stained with 2,3,5-triphenyltetrazolium chloride (TTC). In a blinded analysis, infarct volume was calculated by using computer-aided morphometry to measure brain areas not stained with TTC. After progesterone or allopregnanolone treatment, stained sections revealed a significant reduction in cortical, caudate-putamen, and hemispheric infarct volumes (percentage of contralateral structure) compared with vehicle-injected controls. Cortical infarction (percentage of contralateral cortex) was 37.47%±10.57% (vehicle), 25.49%±7.38% (progesterone; P<.05 from vehicle), and 11.40%±7.09% (allopregnanolone; P<.05 from vehicle; P<.05 from progesterone). Caudate-putamen infarction (percentage of contralateral caudate-putamen) was 78.02%±22.81% (vehicle), 48.41%±22.44% (progesterone; P<.05 from vehicle), and 50.44%±10.90% (allopregnanolone; P<.05 from vehicle). Total hemispheric infarction (percentage of contralateral hemisphere) was 24.37%±6.69% (vehicle), 15.95%±3.59% (progesterone; P<.05 from vehicle), and 11.54%±3.71% (allopregnanolone; P<.05 from vehicle). No significant differences in cerebral blood flow between groups and time points during ischemia and early reperfusion were observed, suggesting that the relative ischemic insult was equivalent among all groups. Although progesterone and allopregnanolone are effective in reducing infarct pathology, allopregnanolone is more potent than progesterone in attenuating cortical damage. Our results suggest that both neurosteroids should be examined for safety and efficacy in a clinical trial for ischemic stroke." @default.
- W1996800910 created "2016-06-24" @default.
- W1996800910 creator A5000399399 @default.
- W1996800910 creator A5020824206 @default.
- W1996800910 creator A5050397111 @default.
- W1996800910 creator A5078609577 @default.
- W1996800910 date "2006-04-01" @default.
- W1996800910 modified "2023-10-17" @default.
- W1996800910 title "Allopregnanolone, a Progesterone Metabolite, Is More Effective Than Progesterone in Reducing Cortical Infarct Volume After Transient Middle Cerebral Artery Occlusion" @default.
- W1996800910 cites W1534552882 @default.
- W1996800910 cites W1659707068 @default.
- W1996800910 cites W1966416313 @default.
- W1996800910 cites W1967173911 @default.
- W1996800910 cites W1973986558 @default.
- W1996800910 cites W1978427824 @default.
- W1996800910 cites W1981081429 @default.
- W1996800910 cites W1984259765 @default.
- W1996800910 cites W1984917548 @default.
- W1996800910 cites W1988379838 @default.
- W1996800910 cites W1989990363 @default.
- W1996800910 cites W1994752284 @default.
- W1996800910 cites W1996296046 @default.
- W1996800910 cites W1996660321 @default.
- W1996800910 cites W1999532415 @default.
- W1996800910 cites W2001828472 @default.
- W1996800910 cites W2002348401 @default.
- W1996800910 cites W2002947389 @default.
- W1996800910 cites W2013430111 @default.
- W1996800910 cites W2013857643 @default.
- W1996800910 cites W2014370769 @default.
- W1996800910 cites W2017716389 @default.
- W1996800910 cites W2019653334 @default.
- W1996800910 cites W2029559183 @default.
- W1996800910 cites W2037486805 @default.
- W1996800910 cites W2044273670 @default.
- W1996800910 cites W2047739534 @default.
- W1996800910 cites W2048879756 @default.
- W1996800910 cites W2050139814 @default.
- W1996800910 cites W2053943396 @default.
- W1996800910 cites W2055931315 @default.
- W1996800910 cites W2057290193 @default.
- W1996800910 cites W2057390900 @default.
- W1996800910 cites W2057638542 @default.
- W1996800910 cites W2058269906 @default.
- W1996800910 cites W2060013651 @default.
- W1996800910 cites W2062049334 @default.
- W1996800910 cites W2065518048 @default.
- W1996800910 cites W2065584262 @default.
- W1996800910 cites W2067322239 @default.
- W1996800910 cites W2068210940 @default.
- W1996800910 cites W2068241715 @default.
- W1996800910 cites W2072974386 @default.
- W1996800910 cites W2075564085 @default.
- W1996800910 cites W2084054825 @default.
- W1996800910 cites W2085652502 @default.
- W1996800910 cites W2088955794 @default.
- W1996800910 cites W2091506786 @default.
- W1996800910 cites W2109850800 @default.
- W1996800910 cites W2112505121 @default.
- W1996800910 cites W2115390080 @default.
- W1996800910 cites W2132556691 @default.
- W1996800910 cites W2150122506 @default.
- W1996800910 cites W2150717405 @default.
- W1996800910 cites W2158344314 @default.
- W1996800910 cites W2165904148 @default.
- W1996800910 cites W2169079203 @default.
- W1996800910 cites W2170572556 @default.
- W1996800910 cites W2172099208 @default.
- W1996800910 cites W2324553845 @default.
- W1996800910 cites W4240821981 @default.
- W1996800910 cites W4243341257 @default.
- W1996800910 cites W4245117662 @default.
- W1996800910 cites W4246835056 @default.
- W1996800910 doi "https://doi.org/10.1016/j.annemergmed.2005.12.011" @default.
- W1996800910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16546625" @default.
- W1996800910 hasPublicationYear "2006" @default.
- W1996800910 type Work @default.
- W1996800910 sameAs 1996800910 @default.
- W1996800910 citedByCount "158" @default.
- W1996800910 countsByYear W19968009102012 @default.
- W1996800910 countsByYear W19968009102013 @default.
- W1996800910 countsByYear W19968009102014 @default.
- W1996800910 countsByYear W19968009102015 @default.
- W1996800910 countsByYear W19968009102016 @default.
- W1996800910 countsByYear W19968009102017 @default.
- W1996800910 countsByYear W19968009102018 @default.
- W1996800910 countsByYear W19968009102019 @default.
- W1996800910 countsByYear W19968009102020 @default.
- W1996800910 countsByYear W19968009102021 @default.
- W1996800910 countsByYear W19968009102022 @default.
- W1996800910 countsByYear W19968009102023 @default.
- W1996800910 crossrefType "journal-article" @default.
- W1996800910 hasAuthorship W1996800910A5000399399 @default.
- W1996800910 hasAuthorship W1996800910A5020824206 @default.
- W1996800910 hasAuthorship W1996800910A5050397111 @default.
- W1996800910 hasAuthorship W1996800910A5078609577 @default.
- W1996800910 hasConcept C126322002 @default.
- W1996800910 hasConcept C134018914 @default.